[go: up one dir, main page]

ES2361993T5 - Tratamiento con enzimas de productos alimenticios para celiaquía - Google Patents

Tratamiento con enzimas de productos alimenticios para celiaquía Download PDF

Info

Publication number
ES2361993T5
ES2361993T5 ES03711089.7T ES03711089T ES2361993T5 ES 2361993 T5 ES2361993 T5 ES 2361993T5 ES 03711089 T ES03711089 T ES 03711089T ES 2361993 T5 ES2361993 T5 ES 2361993T5
Authority
ES
Spain
Prior art keywords
food products
enzyme treatment
celiac disease
celiac
gluten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03711089.7T
Other languages
English (en)
Other versions
ES2361993T3 (es
Inventor
Felix Hausch
Gary Gray
Lu Shan
Chaitan Khosla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2361993(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of ES2361993T3 publication Critical patent/ES2361993T3/es
Application granted granted Critical
Publication of ES2361993T5 publication Critical patent/ES2361993T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25

Claims (1)

  1. imagen1
    imagen2
ES03711089.7T 2002-02-14 2003-02-14 Tratamiento con enzimas de productos alimenticios para celiaquía Expired - Lifetime ES2361993T5 (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US35723802P 2002-02-14 2002-02-14
US357238P 2002-02-14
US38076102P 2002-05-14 2002-05-14
US380761P 2002-05-14
US39278202P 2002-06-28 2002-06-28
US392782P 2002-06-28
US42293302P 2002-10-31 2002-10-31
US422933P 2002-10-31
US42803302P 2002-11-20 2002-11-20
US428033P 2002-11-20
US43588102P 2002-12-20 2002-12-20
US435881P 2002-12-20
PCT/US2003/004743 WO2003068170A2 (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue

Publications (2)

Publication Number Publication Date
ES2361993T3 ES2361993T3 (es) 2011-06-27
ES2361993T5 true ES2361993T5 (es) 2014-12-09

Family

ID=27739509

Family Applications (2)

Application Number Title Priority Date Filing Date
ES03711089.7T Expired - Lifetime ES2361993T5 (es) 2002-02-14 2003-02-14 Tratamiento con enzimas de productos alimenticios para celiaquía
ES11177678T Expired - Lifetime ES2706911T3 (es) 2002-02-14 2003-02-14 Tratamiento enzimático de alimentos para celíacos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11177678T Expired - Lifetime ES2706911T3 (es) 2002-02-14 2003-02-14 Tratamiento enzimático de alimentos para celíacos

Country Status (9)

Country Link
US (8) US7303871B2 (es)
EP (3) EP2364718B1 (es)
AT (1) ATE505201T1 (es)
AU (1) AU2003215272B2 (es)
CA (1) CA2475972C (es)
DE (1) DE60336754D1 (es)
DK (2) DK2364718T3 (es)
ES (2) ES2361993T5 (es)
WO (1) WO2003068170A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
DK2364718T3 (en) * 2002-02-14 2016-10-03 Univ Leland Stanford Junior Enzyme treatment of foods for celiac disease
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
WO2004045392A2 (en) * 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
DK1663298T3 (da) * 2003-09-23 2019-10-14 Dsm Ip Assets Bv Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
CA2564521C (en) 2004-04-28 2017-04-11 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP1949093A2 (en) * 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
US20090304754A1 (en) * 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
US8071089B2 (en) * 2005-11-01 2011-12-06 Bio-Cat, Inc. Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US8637325B2 (en) * 2009-02-16 2014-01-28 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
DE102007011515A1 (de) 2007-03-09 2008-09-11 Kampffmeyer Food Innovation Gmbh Verfahren zur Behandlung eines Getreidemahlerzeugnisses zum Abbau von zöliakieaktiven Proteinen
MX2009009780A (es) 2007-03-16 2010-05-20 Univ Leland Stanford Junior Terapia de enzima de combinacion para la digestion de gluten dietetico.
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
WO2010021752A1 (en) * 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
EP2344183B1 (en) * 2008-10-10 2015-02-25 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of zymogen
EP2367561B1 (en) 2008-11-30 2015-05-20 Immusant, Inc. Compositions and methods for treatment of celiac disease
JP2012515173A (ja) * 2009-01-15 2012-07-05 グルウタゲン ピーティワイ リミテッド グルテン不耐症の治療のための組成物及びその使用
EP2778685B1 (en) 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US20120107847A1 (en) 2009-07-02 2012-05-03 Dsm Ip Assets B.V. Testing efficacy for celiac disease
WO2011044365A1 (en) 2009-10-07 2011-04-14 Trustees Of Boston University Rothia species glutamine endopeptidases and use thereof
US9011842B2 (en) 2010-02-02 2015-04-21 Amano Enzyme Inc. Use of proteases for gluten intolerance
EP3604558B1 (en) 2010-02-17 2022-10-12 Gen-Probe Incorporated Compositions and methods to detect atopobium vaginae nucleic acid
WO2011112792A1 (en) * 2010-03-10 2011-09-15 IMMCO Diagnostics, Inc. Compositions and methods for determining celiac disease
WO2011126873A2 (en) * 2010-03-30 2011-10-13 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
US9598684B2 (en) 2010-07-07 2017-03-21 Trustees Of Boston University Rothia species gluten-degrading enzymes and uses thereof
WO2012135646A2 (en) * 2011-03-30 2012-10-04 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
US20140205587A1 (en) * 2011-06-17 2014-07-24 Alvine Pharmaceuticals, Inc. Proteases for Degrading Gluten
ES2677850T3 (es) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Composiciones y métodos probióticos
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
HUE037870T2 (hu) 2011-08-10 2018-09-28 Univ Washington Through Its Center For Commercialization Készítmények és módszerek lisztérzékenység kezelésére
JP6203743B2 (ja) * 2011-12-06 2017-09-27 フオンダツイオーネ・イステイトウート・インスブリコ・デイ・リチエルカ・ペル・ラ・ビータ アクチノミセス・アクチノアロムルス（ＡＣＴＩＮＯＭＹＣＥＴＥＡＣＴＩＮＯＡＬＬＯＭＵＲＵＳ）由来の、酸性ｐＨにてグルテンペプチドおよびタンパク質を加水分解できる新規プロテアーゼ
PL3901164T3 (pl) * 2012-06-18 2025-04-14 H.J. Heinz Company Brands Llc Zaburzenia związane z glutenem
ITRM20120468A1 (it) * 2012-10-02 2014-04-03 Uni Degli Studi Di Foggia Metodo per la detossificazione delle proteine del glutine dalla granella dei cereali
US9005610B2 (en) 2012-11-21 2015-04-14 Nepetx, Llc Treatment of gluten intolerance and related conditions
US10434150B2 (en) 2013-01-23 2019-10-08 Immunogenics Llc Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
CA2906044A1 (en) * 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
EP3753571A1 (en) 2013-03-15 2020-12-23 Nepetx LLC Treatment of gluten intolerance and related conditions
DK2994150T3 (da) 2013-05-10 2019-06-11 Heinz Co Brands H J Llc Probiotika og fremgangsmåde til anvendelse
CN105555300A (zh) 2013-08-14 2016-05-04 华盛顿大学商业中心 用于治疗口炎性腹泻的组合物和方法
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition
EP2883458A1 (en) * 2013-12-11 2015-06-17 DSM IP Assets B.V. Medicament and method for treating innate immune response diseases
WO2015177152A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
WO2015177153A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
US10450554B2 (en) 2014-05-19 2019-10-22 Dsm Ip Assets B.V. Proline specific endoprotease
DK3220946T3 (da) 2014-06-16 2021-08-02 Codexis Inc Sammensætninger og fremgangsmåder til dæmpning og forebyggelse af tarminflammation på grund af tilstedeværelsen af peptidiske fødevareantigener i tarmen
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease
US10793846B2 (en) 2015-06-08 2020-10-06 University Of Washington Compositions and methods for treating celiac sprue disease
WO2017106798A2 (en) 2015-12-16 2017-06-22 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
ITUB20159442A1 (it) 2015-12-17 2017-06-17 New Gluten World Srl Metodo di detossificazione delle proteine del glutine dalle granaglie dei cereali e relativi usi in campo medico
US10702590B2 (en) 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
WO2018098082A1 (en) 2016-11-23 2018-05-31 Immunogenics, Llc Latiglutenase (alv003) for use in the treatment of symptomatic celiac disease, gluten intolerance or gluten sensitivity
WO2020120737A1 (en) 2018-12-13 2020-06-18 Dsm Ip Assets B.V. Umami flavour composition
IT201900012942A1 (it) 2019-07-25 2021-01-25 Nemysis Ltd Metodo per la produzione di una composizione enzimatica comprendente una endopeptidasi ricombinante
US20220364069A1 (en) 2019-07-25 2022-11-17 Nemysis Limited Method for the production of an enzymatic composition comprising a recombinant endopeptidase
WO2021254943A1 (en) 2020-06-17 2021-12-23 Dsm Ip Assets B.V. Umami flavour composition
US11939300B2 (en) 2020-08-21 2024-03-26 Immunomolecular Therapeutics, Inc. Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2451388A1 (de) 1973-10-31 1975-05-07 James Joseph Phelan Verfahren zur entgiftung von kleber in nahrungsmitteln
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4203967A (en) 1977-01-13 1980-05-20 Hoffmann-La Roche Inc. Diagnostic test for malabsorption
US4562003A (en) * 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
AU599636B2 (en) 1986-03-14 1990-07-26 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4912120A (en) * 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
US4929630A (en) 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
DD262999A1 (de) 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9225021D0 (en) * 1992-11-30 1993-01-20 Sandoz Ltd Organic compounds
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
WO1995021190A1 (en) * 1994-02-07 1995-08-10 The United States Of America, Represented By The Secretary Of Agriculture Detection of wheat that has experienced elevated temperatures during the grain filling period
WO1996010034A2 (en) 1994-09-29 1996-04-04 Merck & Co., Inc. Thiol-free inhibitors of farnesyl-protein transferase
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
GB9509336D0 (en) * 1995-05-09 1995-06-28 Dynal As Chemical method
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20020018763A1 (en) * 1995-05-24 2002-02-14 Kriszkina M. Zsebo A method of stimulating growth of stromal cells with stem cell factor (scf) polypeptides
DE19630557C2 (de) * 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5817523A (en) 1996-07-24 1998-10-06 Picarelli; Antonio Method and kit for confirming in vitro diagnosis of coeliac disease
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6008027A (en) 1997-07-17 1999-12-28 Langner; Bruce J. Enteric polymer coated capsule containing dried bacterial culture for supplying lactase
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US20020052026A1 (en) * 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
CZ301925B6 (cs) 1997-12-31 2010-08-04 Pfizer Products Inc. Azapolycyklické deriváty s anelovanou arylskupinou, jejich použití, farmaceutické kompozice na jejich bázi a meziprodukty pro jejich výrobu
WO1999056698A2 (en) 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
US6201695B1 (en) * 1998-10-26 2001-03-13 Micron Technology, Inc. Heat sink for chip stacking applications
AU3110500A (en) 1998-12-04 2000-06-19 Barnes-Jewish Hospital Cell matrix plaques of initial bone formation
AU3208200A (en) 1999-01-13 2000-08-01 Research Foundation Of The State University Of New York, The A novel method for designing protein kinase inhibitors
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6962989B1 (en) 1999-07-08 2005-11-08 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding novel proteins
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
AU7878900A (en) * 1999-10-15 2001-04-30 Heska Corporation Method for production and use of mite group 1 proteins
US6492498B1 (en) * 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US6642036B2 (en) * 2000-07-07 2003-11-04 E. I. Du Pont De Nemours And Company Sinapoylglucose:malate sinapoyltransferase form malate conjugates from benozic acid glucosides
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
EP2175013A1 (en) * 2000-12-07 2010-04-14 DSM IP Assets B.V. Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
ES2220835T3 (es) * 2000-12-07 2004-12-16 Dsm Ip Assets B.V. Metodo para la prevencion o reduccion del enturbiamiento en bebidas.
EP1360192A1 (en) * 2001-01-16 2003-11-12 Kobenhavns Universitet A method for refolding of proteins
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002083722A2 (en) * 2001-04-12 2002-10-24 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
US6645739B2 (en) * 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
NO20015814D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Metallkompleksforbindelser
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
DK2364718T3 (en) * 2002-02-14 2016-10-03 Univ Leland Stanford Junior Enzyme treatment of foods for celiac disease
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US20030224476A1 (en) 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
WO2004045392A2 (en) 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US6903246B2 (en) * 2002-05-28 2005-06-07 The Regents Of The University Of California Dehydroascorbate reductase (“DHAR”) genes from Triticum aestivum and their use to modulate ascorbic acid levels in plants
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
CN1311076C (zh) * 2003-04-16 2007-04-18 普罗特奥姆技术公司 生产重组尿激酶的方法
US20050049064A1 (en) * 2003-09-02 2005-03-03 Gagne Robert M. Golf training apparatus
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2005058930A2 (en) * 2003-12-11 2005-06-30 Proteomtech Inc. Methods for production of recombinant vascular endothelial cell growth inhibitor
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7521427B2 (en) * 2004-11-09 2009-04-21 Georgia Tech Research Corporation Peptidyl allyl sulfones
EP1949093A2 (en) * 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
US20090304754A1 (en) 2005-10-12 2009-12-10 Srebrenka Robic Pegylated glutenase polypeptides
WO2007050795A2 (en) * 2005-10-25 2007-05-03 Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof
US20070099238A1 (en) * 2005-10-31 2007-05-03 Sigalas Mihail M Enhancement of emission using metal coated dielectric nanoparticles
EP1845103B1 (en) * 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
MX2009009780A (es) 2007-03-16 2010-05-20 Univ Leland Stanford Junior Terapia de enzima de combinacion para la digestion de gluten dietetico.
WO2010021752A1 (en) 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
EP2344183B1 (en) 2008-10-10 2015-02-25 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of zymogen

Also Published As

Publication number Publication date
DK1572127T4 (da) 2014-11-24
DK1572127T3 (da) 2011-07-25
US20080213822A1 (en) 2008-09-04
US7943312B2 (en) 2011-05-17
DK2364718T3 (en) 2016-10-03
EP1572127A4 (en) 2009-03-18
US20030215438A1 (en) 2003-11-20
CA2475972C (en) 2017-07-11
DE60336754D1 (de) 2011-05-26
US7303871B2 (en) 2007-12-04
US7923532B2 (en) 2011-04-12
EP1572127B2 (en) 2014-10-29
US20170119860A1 (en) 2017-05-04
EP1572127A2 (en) 2005-09-14
AU2003215272B2 (en) 2008-04-03
US20080213427A1 (en) 2008-09-04
ES2361993T3 (es) 2011-06-27
ATE505201T1 (de) 2011-04-15
US20080213245A1 (en) 2008-09-04
ES2706911T3 (es) 2019-04-01
EP2409711B1 (en) 2018-11-21
WO2003068170A2 (en) 2003-08-21
US8962545B2 (en) 2015-02-24
US7910541B2 (en) 2011-03-22
EP2409711A1 (en) 2012-01-25
US20090280555A1 (en) 2009-11-12
EP1572127B1 (en) 2011-04-13
US20080145356A1 (en) 2008-06-19
EP2364718A1 (en) 2011-09-14
EP2364718B1 (en) 2016-07-06
AU2003215272A1 (en) 2003-09-04
CA2475972A1 (en) 2003-08-21
WO2003068170A3 (en) 2008-07-03
US7928056B2 (en) 2011-04-19
US20110293724A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
ES2361993T5 (es) Tratamiento con enzimas de productos alimenticios para celiaquía
WO2003096979A3 (en) Drug therapy for celiac sprue
CY1110606T1 (el) Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου
EE05434B1 (et) Farmatseutiliselt aktiivsed uridiiniestrid
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
DK0533781T3 (da) 3-aryl-2-hydroxypropionsyrederivater og -analoger som hypoglykæmiske midler
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
WO2004073647A3 (en) Ultrasonically enhanced saline treatment for burn damaged skin
CY1113600T1 (el) Θεραπειες συνδυασμου για λεμφωματα β-κυτταρου που περιλαμβανουν χορηγηση anti-cd20 αντισωματος
WO2003009884A3 (en) Elongated syringe
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
AR046970A1 (es) Esteres de fosfato de florfenicol
TR200400526T4 (tr) Göz kurumasının tedavisi için lipoksin A4 ve analogları
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
CY1111273T1 (el) Συνδυασμενη χρηση της l-καρνιτινης, ακετυλο l-καρνιτινης και προπιονυλο l-καρνιτινης για τη θεραπεια της ολιγοασθενοτερατοσπερμιας
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
DE60222895D1 (de) Linderung von fehlern in der augenkontrollfunktion
PT1368016E (pt) Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
EA200702356A1 (ru) Средство для предотвращения прогрессирования апоптотических изменений в клетках различных органов и их перехода в некротическое поражение